RecruitingNCT06394934

Home Blood Pressure Variability and Its Link to Arteriosclerosis and Metabolic Dysfunction in Hypertensive Patients

Impact of Home and Clinical Blood Pressure Variability on Arteriosclerosis and Metabolic Indicators


Sponsor

Korea University Anam Hospital

Enrollment

4,188 participants

Start Date

Jan 9, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

This observational study investigates the correlation between home blood pressure variability (BPV) and arteriosclerosis, alongside metabolic indicators, in hypertensive patients over a three-year period. The research specifically focuses on the predictive value of home BPV for major adverse cardiovascular events (MACE) including myocardial infarction, stroke, and heart failure hospitalizations. Utilizing a mobile application called Healthscan for daily BP monitoring, the study aims to enhance the understanding of how BPV impacts cardiovascular and metabolic health in a real-world setting.


Eligibility

Min Age: 19 Years

Inclusion Criteria5

  • Adults aged 19 years or older.
  • Diagnosed with hypertension.
  • Regular use of antihypertensive medication for at least two years.
  • Access to a home blood pressure monitor.
  • Comprehensive medical records available for the past year.

Exclusion Criteria1

  • \. Participants who are unable to consent or who might not reliably use the home monitoring app.

Interventions

BEHAVIORALHealthscan App

Participants will use the Healthscan mobile application to monitor and record their daily blood pressure at home. The app allows participants to enter their BP measurements, which are then used to calculate blood pressure variability (BPV). The app's use is intended as a non-invasive, practical tool for patient self-management and longitudinal health monitoring in hypertensive individuals.


Locations(2)

Korea University Anam Hospital

Seoul, South Korea

Korea Univeristy Guro Hospital

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06394934


Related Trials